March 19, 2020

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 26, 2020

March 19, 2020

TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder to Treat Invasive Pulmonary Aspergillosis (IPA)

March 12, 2020

TFF Pharmaceuticals Announces Engagement of J.S. Cole & Associates as Strategic Advisor for Partnering Efforts in Japan

March 9, 2020

TFF Pharmaceuticals Announces Engagement of Torreya Partners, LLC as Strategic Advisor for Partnering Efforts in China and South Korea

January 28, 2020

Ascend Capital Founder Malcolm Fairbairn Appointed to TFF Pharmaceuticals Board of Directors

January 28, 2020

TFF Pharmaceuticals Reports Continued Progress Across Programs in Corporate Update

January 7, 2020

TFF Pharmaceuticals’ Scientific Consultant Robert O. Williams III Named to National Academy of Inventors

December 11, 2019

TFF Pharmaceuticals to Meet with Investors and Commercial Partners in San Francisco during the JP Morgan Healthcare Conference

December 9, 2019

TFF Pharmaceuticals Reports Third Quarter Results and Provides Business Update

November 25, 2019

TFF Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Voriconazole Inhalation Powder, to Treat Invasive Pulmonary Aspergillosis (IPA)